INSERM UMR U1122, IGE-PCV, Gene-Environment Interactions in Cardio-Vascular Physiopathology, Faculty of Pharmacy - University of Lorraine, Nancy, 54000, France.
INSERM UMR U1122, IGE-PCV, Gene-Environment Interactions in Cardio-Vascular Physiopathology, Faculty of Pharmacy - University of Lorraine, Nancy, 54000, France,
Front Biosci (Landmark Ed). 2018 Mar 1;23(9):1628-1654. doi: 10.2741/4664.
Telomere length has been subject of studies for many decades, aiming to elucidate its role in physiological processes, in process of aging and in diverse pathologies. Yet today, there is still no "big title" discovery that would lead to a practical use of telomeres as a reliable biomarker or target for a new drug. However, therapies for chronic disease patients are being tested and companies are already offering commercial tests for telomere length measurement. The strong genetic heritability of telomeres is opening the place for pharmacogenomics researches that could promote the personalized treatment of diverse diseases. In this article, we present the recent knowledge of telomeres genetic determination obtained by genome-wide association studies (GWAS), important biomarkers related to telomere length and review the possibilities of telomere's practical implementation in the medical treatment of diverse diseases and as a potential biomarker in personalized medicine. Furthermore, we summarise commercial offers of telomere length measurements available and we discuss the actions that should be taken to make steps forward into final application of the accumulated knowledge into practical use.
端粒长度已经成为数十年来的研究课题，旨在阐明其在生理过程、衰老过程和各种病理过程中的作用。然而，时至今日，仍然没有一项“重大发现”能够将端粒用作可靠的生物标志物或新药靶点。但是，针对慢性疾病患者的治疗方法正在进行测试，并且一些公司已经提供了用于测量端粒长度的商业测试。端粒具有很强的遗传遗传性，这为药物遗传学研究开辟了道路，这种研究可能会促进各种疾病的个性化治疗。在本文中，我们介绍了通过全基因组关联研究（GWAS）获得的端粒遗传决定因素的最新知识，以及与端粒长度相关的重要生物标志物，并回顾了端粒在治疗各种疾病和作为个性化医学中潜在生物标志物的实际应用的可能性。此外，我们总结了现有的端粒长度测量商业报价，并讨论了为将积累的知识最终应用于实际应用而应采取的措施。
